^
Association details:
| Biomarker: | CBL mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Excerpt:
...Detectable FLT3-ITD mutation in bone marrow and/or peripheral blood, or presence of CBL exon 8 or 9 deletions or point mutations....
Trial ID:
Source:
Title:
INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION
Published date:
05/12/2022
Excerpt:
We designed a phase I/II study of azacitidine in combination with quizartinib for pts with newly diagnosed or previously treated MDS or MDS/MPN with detectable FLT3 and/or CBL mutations….Preliminary data suggest azacitidine in combination with quizartinib for pts with MDS and MDS/MPN with FLT3 or CBL mutations have an acceptable toxicity profile and associated with promising responses.
Source:
Title:
Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
Published date:
11/04/2021
Excerpt:
We designed a phase I/II clinical trial of Azacitidine in Combination with quizartinib for newly diagnosed patients with MDS...Four patients were enrolled due to FLT3 mutations and 2 due to CBL mutations....All patients have achieved response so far with a total of 5 patients (67%) having achieved marrow CR (mCR) including HI in 1 patient...Preliminary data suggest azacitidine in combination with quizartinib for patients with MDS and MDS/MPN with FLT3 or CBL mutations...
DOI:
10.1182/blood-2021-153189
